The 32nd Annual Meeting of the European Society for Gene & Cell Therapy (ESGCT) will be held in Seville, Spain, from 7 to 10 October 2025.
It brings together scientists working in the fields of gene and cell therapy from Europe and beyond, and highlights the latest advances in research and techniques in this field.
Two experts from the Institute of Myology will present their work:
> Thursday 9 October – Session 9b: AAVs/Non-Integrative Vectors II: Mechanism & Biology
Ines Akrouf, a third-year PhD student supervised by Sofia Benkhelifa-Ziyyat (CRM Muscle Cell Organisation and Dominant Centronuclear Myopathy Therapy team) will give an oral presentation: Efficacy of AAV vectors and optimisation of therapies in mouse models of Duchenne muscular dystrophy and Dynamin 2-related dominant centronuclear myopathy. This study provides proof of principle that selective stimulation of the autophagic pathway by a pharmacological compound, administered at the time of low-dose AAV injection, increases the number of viral genomes and the expression of therapeutic transgenes in diseased muscle.
> Pierre Meunier, Research Engineer at the MyoVector platform, will present a poster describing the production of AAV vectors for CRM research teams: Optimisation of a scalable production process of Adeno-Associated Virus Vectors for research purposes and development of an AAV vector catalogue to target subcellular compartments
